ArticleJournal of robotic surgery2025
Optimal surgical approach for cT3/T4 rectal cancer post-neoadjuvant chemoradiotherapy: robotic surgery versus TaTME guided by superior pelvic diaphragm localization.
Article in Journal of robotic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two emerging techniques for mid-low rectal cancer treatment include robotic surgery (RoTME), and transanal total mesorectal excision (taTME). Additionally, using the superior pelvic diaphragm as a landmark helps protect pelvic autonomic nerves and reduces intraoperative risks. This study compares the long-term oncological and functional outcomes of taTME and RoTME in cT3/cT4 patients after neoadjuvant therapy using propensity score matching, while also evaluating the role of the superior pelvic diaphragm as a surgical guide. We retrospectively analyzed patients who underwent proctectomy between February 2017 and May 2019. After applying strict inclusion criteria, propensity score matching was performed. Additionally, we identified and included patients with a difficult pelvis for further analysis. Oncological outcomes were assessed using 3- and 5-year disease-free survival (DFS) and overall survival (OS), visualized with Kaplan-Meier curves. Pelvic nerve preservation was evaluated based on urinary dysfunction, while anal function was measured using the LARS score questionnaire. 75 patients underwent taTME and 203 underwent RoTME. After 1:2 propensity score matching, the groups comprised 75 taTME and 150 RoTME patients. All patients completed 60-month oncological follow-up, with anal function assessed at six months postoperatively. Compared to RoTME, taTME showed a lower anastomotic leak incidence but higher rate of diverting stomas, despite comparable baseline data.No significant differences were observed in intraoperative complications, functional outcomes, or long-term survival. Notably, identifying the superior pelvic diaphragm intraoperatively aided pelvic nerve preservation. Both RoTME and taTME prove feasible for treating cT3/cT4 lower rectal cancer post-nCRT. When performed beyond the learning curve, these techniques represent safe and reliable surgical options.
Indexed as
Identifiers
41315161What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.